Novo Nordisk released its 2025 financial report: Semaglutide sales reached 2282.88 billion Danish kroner, with promising prospects for the innovative drug pipeline.

On February 4th, Novo Nordisk A/S Sponsored ADR Class B (NVO.US) released its financial report for 2025. Novo Nordisk A/S Sponsored ADR Class B's total annual sales reached 309.1 billion Danish kroner, a 10% increase when calculated at fixed exchange rates. The total annual sales of the Semaglutide series drugs reached 228.288 billion Danish kroner. Sales of the blood sugar-lowering Semaglutide injection Ozempic (known domestically as Noritian) were 127.089 billion Danish kroner, while the weight-loss version, the Semaglutide injection Wegovy (known domestically as Noro Ying), was 79.106 billion Danish kroner. Sales of the blood sugar-lowering Semaglutide oral tablets (known domestically as Noro Xin) were 22.093 billion Danish kroner. Since the launch of Wegovy tablets (a daily 25 mg oral Semaglutide tablet) in the US on January 5th, total weekly prescriptions have reached approximately 50,000. Novo Nordisk A/S Sponsored ADR Class B has submitted a supplemental new drug application to the US Food and Drug Administration (FDA) for the 7.2 mg weight-loss version of the Semaglutide injection. Additionally, Novo Nordisk A/S Sponsored ADR Class B is awaiting approval for new therapies, including Mim8 in the treatment of hemophilia and CagriSema in the treatment of obesity. Novo Nordisk A/S Sponsored ADR Class B is a leader in the GLP-1 market and insulin market for diabetes treatment in the Greater China region, and maintains high growth in the obesity and rare disease markets.